Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

The Hovione Experience - Lisbon

Welcome to Lisbon! Part of The Hovione Experience is ensuring your trip is unforgettable. Explore our suggestions for iconic attractions, exquisite cuisine, and get ready to feel the magic of this vibrant city.

Page
Read more

Continuous Tableting - Virtual Visit

Welcome to the future of drug product development

Page
Read more

Inhalation devices

Hovione’s inhalers offer our business partners access to simple, multipurpose, easy to use, globally competitive alternatives for inhalation delivery devices.

Page
Read more